Pelvic exenteration for locally advanced and recurrent prostate cancer

Locally advanced or recurrent prostate cancer which invades adjacent pelvic organs, bone or other soft tissue structures is a rare situation. This study aimed to report the outcomes of ten consecutive patients who underwent total pelvic exenteration for prostate cancer at a high -volume specialist centre. Two patients had locally advanced primary tumours, while eight had locally recurrent prostate cancer. Median operating time, blood loss, ICU stay, and hospital stay was 12.2 h (range 9.6 -13.8), 2500 ml (500 -3000), 4.5 days (2 -7) and 36 days (21 -78), respectively. There was no inpatient, 30-day, or 90-day mortality. Six patients developed a ClavienDindo III complication. R0 resection was achieved in eight patients. Median follow up was 16 months (range 2 -77). At last follow up, five patients were alive without disease. These findings suggest that pelvic exenteration for locally advanced and recurrent prostate cancer is safe and represents a potentially curative treatment option for highly selected patients.